Circular Genomics launches antidepressant response test

Katelyn Trinh
Sep 17, 2024
1 min read

The new SSRI antidepressant test uses circular RNA biomarkers to improve precision in psychiatry.

Circular Genomics has introduced MindLight, a test designed to predict the response of patients with depression to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment.

View remaining article on Medical Device Network

Paul Sargeant, PhD, CEO of Circular Genomics Presents at LSI USA '25 - "Circular RNA Biomarkers for Depression Treatment"

Circular Genomics is at the forefront of revolutionizing healthcare by leveraging circular RNA to develop advanced diagnostic tools,...

5 Promising RNA Biotech Companies To Watch in 2025

Circular Genomics: Innovative RNA Solutions to Lead a New Era in Mental Health RNA, often referred to as the “messenger molecule,” plays...

Podcast: "Revolutionizing Depression Treatment with Dr. Nikolaos Mellios"

Circular Genomics' Chief Scientific Officer, Dr. Nikolaos Mellios, M.D., PhD, joins Steven Schwartz on the Concierge Medical Marketing...

Commentaires

Les commentaires sur ce post ne sont plus acceptés. Contactez le propriétaire pour plus d'informations.